


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I



in which

- D denotes phenyl or pyridyl, each of which is unsubstituted or mono- or polysubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR² or CON(R²)₂,
- R¹ denotes A, which is mono-, di- or trisubstituted by S(=O)(=NR²)R², NR²SO₂R², OSO₂R², OSO₂N(R²)₂ or PO(OR²)₂, and may additionally be mono- or disubstituted by OR³, N(R³)₂, CN, COOR³ or CON(R³)₂, and may additionally be mono-, di- or trisubstituted by S(O)_mR², SO₂N(R²)₂, or SO₃R²,
- R² denotes H, A, -[C(R³)₂]_n-Ar', -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-N(R³)₂ or -[C(R³)₂]_n-OR³,
- R³ denotes H or A,
- W denotes -[C(R³)₂]_n-,
- X denotes NR³ or O,
- Y denotes alkylene, cycloalkylene, Het-diyl or Ar-diyl,
- T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms, which may be mono-, di- or trisubstituted by =O, R², Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het, -[C(R³)₂]_n-cycloalkyl, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²CON(R²)₂, NR²SO₂A, COR², SO₂NR² and/or S(O)_nA, or N(R²)₂ and, if Y = piperidine-1,4-diyl, also R² or cycloalkyl,
- A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by F,

- Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²SO₂A, COR², SO₂N(R²)₂, -[C(R³)₂]_n-COOR², -O-[C(R³)₂]_o-COOR², SO₃H or S(O)_nA,
- Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂, S(O)_nA, -[C(R³)₂]_n-COOR³ or -O-[C(R³)₂]_o-COOR³,
- Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen (=O), =S, =N(R²)₂, Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-OR², -[C(R³)₂]_n-N(R³)₂, NO₂, CN, -[C(R³)₂]_n-COOR², -[C(R³)₂]_n-CON(R²)₂, -[C(R³)₂]_n-NR²COA, NR²CON(R²)₂, -[C(R³)₂]_n-NR²SO₂A, COR², SO₂N(R²)₂ and/or S(O)_nA,
- Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, =N(R³)₂, Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂ and/or S(O)_nA,
- Hal denotes F, Cl, Br or I,
- m denotes 1 or 2,
- n denotes 0, 1 or 2, and
- o denotes 1, 2 or 3,
- or a pharmaceutically acceptable salt, ~~hydrate, alcoholate~~ or stereoisomer thereof.

2. (Previously Presented) A compound according to Claim 1, in which
D denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OR² or COOR², or pyridyl which is unsubstituted or monosubstituted by Hal.
3. (Previously Presented) A compound according to Claim 1, in which
D denotes phenyl which is monosubstituted by Hal.
4. (Previously Presented) A compound according to Claim 1, in which
R² denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms.

5. (Previously Presented) A compound according to Claim 1, in which
Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, OH or OA.

6. (Previously Presented) A compound according to Claim 1, in which
Y denotes Ar-diyl.

7. (Previously Presented) A compound according to Claim 1, in which
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR², SO₂A, SO₂NH₂, COOR² or CN.

8. (Previously Presented) A compound according to Claim 1, in which
R¹ denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms which is monosubstituted by S(=O)(=NR²)R², NR²SO₂R², OSO₂R², OSO₂N(R²)₂ or PO(OR²)₂.

9. (Previously Presented) A compound according to Claim 1, in which
X denotes NH or O.

10. (Previously Presented) A compound according to Claim 1, in which
T denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be mono- or disubstituted by =O, OH or OA, or N(R²)₂
and, if Y = piperidine-1,4-diyl, also R² or cycloalkyl.

11. (Previously Presented) A compound according to Claim 1, in which
Y denotes phenylene which is unsubstituted or monosubstituted by A.

12. (Previously Presented) A compound according to Claim 1, in which
n is 0.

13. (Previously Presented) A compound according to Claim 1, in which
D denotes phenyl which is monosubstituted by Hal,

- R^1 denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms which is monosubstituted by $S(=O)(=NR^2)R^2$, $NR^2SO_2R^2$, OSO_2R^2 , $OSO_2N(R^2)_2$ or $PO(OR^2)_2$,
- R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,
- W denotes $-(CH_2)_n-$,
- X denotes NH or O,
- Y denotes Ar-diyl,
- T denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms which is mono- or disubstituted by $=O$, or $N(R^2)_2$ and, if $Y = \text{piperidine-1,4-diyl}$, also R^2 or cycloalkyl,
- A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by $-CH=CH-$ groups and/or also 1-7 H atoms may be replaced by F,
- Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^2 , SO_2A , SO_2NH_2 , $COOR^2$ or CN,
- Hal denotes F, Cl, Br or I,
- m denotes 1 or 2, and
- n denotes 0, 1 or 2.

14. (Previously Presented) A compound according to Claim 1, in which

- D denotes phenyl which is monosubstituted by Hal,
- R^1 denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms which is monosubstituted by $S(=O)(=NR^2)R^2$, $NR^2SO_2R^2$, OSO_2R^2 , $OSO_2N(R^2)_2$ or $PO(OR^2)_2$,
- R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,
- W denotes $-(CH_2)_n-$,
- X denotes NH or O,
- Y denotes Ar-diyl,
- T denotes piperidin-1-yl, 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, pyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, morpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-hydroxy-6-oxopiperazin-1-yl, 2-methoxy-

6-oxopiperazin-1-yl, 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl,
or $N(R^2)_2$

and, if Y = piperidine-1,4-diyl, also R^2 or cycloalkyl,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by $-CH=CH-$ groups and/or also 1-7 H atoms may be replaced by F,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^2 , SO_2A , SO_2NH_2 , $COOR^2$ or CN,

Hal denotes F, Cl, Br or I,

m denotes 1 or 2, and

n denotes 0, 1 or 2.

15. (Previously Presented) A compound according to Claim 1, in which

D denotes phenyl which is monosubstituted by Hal,

R^1 denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms which is monosubstituted by $S(=O)(=NR^2)R^2$, $NR^2SO_2R^2$, OSO_2R^2 , $OSO_2N(R^2)_2$ or $PO(OR^2)_2$,

R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

W denotes $-(CH_2)_n-$,

X denotes NH or O,

Y denotes phenylene which is unsubstituted or monosubstituted by A,

T denotes piperidin-1-yl, 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, pyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, morpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-hydroxy-6-oxopiperazin-1-yl, 2-methoxy-6-oxopiperazin-1-yl, 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl,
or $N(R^2)_2$

and, if Y = piperidine-1,4-diyl, also R^2 or cycloalkyl,


A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by $-CH=CH-$ groups and/or also 1-7 H atoms may be replaced by F,

Y denotes phenylene which is unsubstituted or monosubstituted by A,
Hal denotes F, Cl, Br or I,
m denotes 1 or 2, and
n denotes 0, 1 or 2.

16. (Previously Presented) A compound, which is
2-[3-(4-chlorophenyl)ureido]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-4-methanesulfonylbutyramide,
2-[3-(4-chlorophenyl)ureido]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]-4-methanesulfonylbutyramide,
2-[3-(4-chlorophenyl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methanesulfonylbutyramide,
(*R*)-2-[3-(4-chlorophenyl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methanesulfonylbutyramide,
(*R*)-2-[3-(4-chlorophenyl)ureido]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methanesulfonylpropionamide,
(*S*)-2-[3-(4-chlorophenyl)ureido]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methanesulfonylpropionamide,
(*S*)-2-[*N*-(4-chlorophenyl)carbamoyloxy]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methanesulfonylpropionamide,
(*R*)-2-[*N*-(4-chlorophenyl)carbamoyloxy]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methanesulfonylpropionamide,
(*R*)-2-[3-(4-chlorophenyl)ureido]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-4-methanesulfonylbutyramide,
(*S*)-2-[3-(4-chlorophenyl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methanesulfonylpropionamide,
2-[*N*-(4-chlorophenyl)carbamoyloxy]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methanesulfonylpropionamide,
2-[3-(4-chlorophenyl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-sulfopropionamide,
2-[3-(4-chlorophenyl)ureido]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-sulfopropionamide,

(S)-2-[3-(4-chlorophenyl)ureido]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(dimethoxyphosphoryl)propionamide,
 2-[3-(4-chlorophenyl)ureido]-N-[4-(2-oxopiperidin-1-yl)phenyl]-3-(dimethoxyphosphoryl)propionamide,
 2-[3-(4-chlorophenyl)ureido]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-phosphonopropionamide,
 2-[3-(4-chlorophenyl)ureido]-N-[4-(3-oxomorpholin-4-yl)phenyl]-4-(methanesulfoximiny)butyramide,
 2-[3-(4-chlorophenyl)ureido]-N-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-sulfamoylpropionamide,
 2-[3-(4-chlorophenyl)ureido]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-methanesulfonylaminopropionamide,
 2-[3-(4-chlorophenyl)ureido]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-sulfamoyloxypropionamide,
 (R)-2-[3-(4-chlorophenyl)ureido]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methanesulfonylpropionamide,
 (R)-2-[3-(4-chlorophenyl)ureido]-N-[4-(2-oxo-1,3-oxazinan-3-yl)phenyl]-3-methanesulfonylpropionamide,
 (R)-2-[3-(4-chlorophenyl)ureido]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methanesulfonylbutyramide,
 (R)-2-[3-(4-chlorophenyl)ureido]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-sulfamoyloxypropionamide,
 (R)-2-[3-(4-chlorophenyl)ureido]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(dimethoxyphosphoryl)propionamide,
 (R)-2-[3-(4-chlorophenyl)ureido]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(dimethoxyphosphoryl)propionamide, or
 (S)-2-[3-(4-chlorophenyl)ureido]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(dimethoxyphosphoryl)propionamide.

17. (Withdrawn) A process for preparing a compound of formula I according to Claim 1, comprising
- a) reacting a compound of formula II



in which

R^1 , T, W, X and Y have the meaning indicated for the compound of formula I,

with a compound of formula III



in which

D has the meaning indicated for the compound of formula I,


or

b) reacting a compound of formula IV



in which W, Y and T have the meaning indicated for the compound of formula I,

with a compound of formula V



in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group and R^1 , X and D have the meanings indicated for the compound of formula I,

or

c) a radical R^1 is converted into another radical R^1 by oxidizing the radical R^1 ,

and/or a base or acid of a compound of formula I is converted into one of its salts.

18. (Withdrawn) A method for inhibiting coagulation factor Xa, comprising administering an effective amount of a compound of claim 1.

19. (Withdrawn) A method for inhibiting coagulation factor VIIa, comprising administering an effective amount of a compound of claim 1.

20. (Previously Presented) A pharmaceutical composition, comprising at least one compound of formula I according to Claim 1 and a pharmaceutically acceptable excipient and/or adjuvant.

21. (Previously Presented) A pharmaceutical composition according to claim 20, further comprising a further pharmaceutically active ingredient.


22. (Withdrawn) A method for treating thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, a tumor, a tumor disease or tumor metastases, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 20.

23. (Previously Presented) A set or kit comprising separate packs of
(a) a compound of formula I according to Claim 1, and
(b) a further pharmaceutically active ingredient.

24. (Withdrawn) A method according to claim 22, further comprising administering a further pharmaceutically active ingredient.

25. (Cancelled)

26. (Previously Presented) A compound of formula I



in which

- D denotes phenyl or pyridyl, each of which is unsubstituted or mono- or polysubstituted by Hal, A, OR^2 , $\text{N}(\text{R}^2)_2$, NO_2 , CN, COOR^2 or $\text{CON}(\text{R}^2)_2$,
- R^1 denotes A, which is mono-, di- or trisubstituted by $\text{SO}_2\text{N}(\text{R}^{2'})_2$, $\text{SO}_3\text{R}^{2'}$, $\text{S}(=\text{O})(=\text{NR}^{2'})\text{R}^2$, $\text{NR}^2\text{SO}_2\text{R}^2$, OSO_2R^2 , $\text{OSO}_2\text{N}(\text{R}^2)_2$ or $\text{PO}(\text{OR}^2)_2$ and may additionally be mono- or disubstituted by OR^3 , $\text{N}(\text{R}^3)_2$, CN, COOR^3 or $\text{CON}(\text{R}^3)_2$, and may additionally be mono-, di- or trisubstituted by $\text{S}(\text{O})_m\text{R}^2$, $\text{SO}_2\text{N}(\text{R}^2)_2$, or SO_3R^2 ,
- R^2 denotes H, A, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-Ar}'$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-Het}'$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-cycloalkyl}$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-N}(\text{R}^3)_2$ or $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-OR}^3$,
- $\text{R}^{2'}$ denotes $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-Ar}'$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-Het}'$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-cycloalkyl}$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-N}(\text{R}^3)_2$ or $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-OR}^3$,
- R^3 denotes H or A,
- W denotes $-\text{[C}(\text{R}^3)_2\text{]}_n-$,
- X denotes NR^3 or O,
- Y denotes alkylene, cycloalkylene, Het-diyl or Ar-diyl,
- T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms, which may be mono-, di- or trisubstituted by $=\text{O}$, R^2 , Hal, A, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-Ar}$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-Het}$, $-\text{[C}(\text{R}^3)_2\text{]}_n\text{-cycloalkyl}$, OR^2 , $\text{N}(\text{R}^2)_2$, NO_2 , CN, COOR^2 , $\text{CON}(\text{R}^2)_2$, NR^2COA , $\text{NR}^2\text{CON}(\text{R}^2)_2$, $\text{NR}^2\text{SO}_2\text{A}$, COR^2 , SO_2NR^2 and/or $\text{S}(\text{O})_n\text{A}$,
or $\text{N}(\text{R}^2)_2$
and, if $\text{Y} = \text{piperidine-1,4-diyl}$, also R^2 or cycloalkyl,
- A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by $-\text{CH}=\text{CH}-$ groups and/or also 1-7 H atoms may be replaced by F,

- Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^2 , $N(R^2)_2$, NO_2 , CN, $COOR^2$, $CON(R^2)_2$, NR^2COA , NR^2SO_2A , COR^2 , $SO_2N(R^2)_2$, $-[C(R^3)_2]_n-COOR^2$, $-O-[C(R^3)_2]_o-COOR^2$, SO_3H or $S(O)_nA$,
- Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^3 , $N(R^3)_2$, NO_2 , CN, $COOR^3$, $CON(R^3)_2$, NR^3COA , $NR^3CON(R^3)_2$, NR^3SO_2A , COR^3 , $SO_2N(R^3)_2$, $S(O)_nA$, $-[C(R^3)_2]_n-COOR^3$ or $-O-[C(R^3)_2]_o-COOR^3$,
- Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen ($=O$), $=S$, $=N(R^2)_2$, Hal, A, $-[C(R^3)_2]_n-Ar$, $-[C(R^3)_2]_n-Het'$, $-[C(R^3)_2]_n$ -cycloalkyl, $-[C(R^3)_2]_n-OR^2$, $-[C(R^3)_2]_n-N(R^3)_2$, NO_2 , CN, $-[C(R^3)_2]_n-COOR^2$, $-[C(R^3)_2]_n-CON(R^2)_2$, $-[C(R^3)_2]_n-NR^2COA$, $NR^2CON(R^2)_2$, $-[C(R^3)_2]_n-NR^2SO_2A$, COR^2 , $SO_2N(R^2)_2$ and/or $S(O)_nA$,
- Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, $=S$, $=N(R^3)_2$, Hal, A, OR^3 , $N(R^3)_2$, NO_2 , CN, $COOR^3$, $CON(R^3)_2$, NR^3COA , $NR^3CON(R^3)_2$, NR^3SO_2A , COR^3 , $SO_2N(R^3)_2$ and/or $S(O)_nA$,
- Hal denotes F, Cl, Br or I,
- m denotes 1 or 2,
- n denotes 0, 1 or 2, and
- o denotes 1, 2 or 3,
- or a pharmaceutically acceptable salt thereof.

27. (Previously Presented) A compound according to Claim 1, in which R^1 denotes A, which is mono-, di- or trisubstituted by $NR^2SO_2R^2$, OSO_2R^2 , $OSO_2N(R^2)_2$ or $PO(OR^2)_2$, and may additionally be mono- or disubstituted by OR^3 , $N(R^3)_2$, CN, $COOR^3$ or $CON(R^3)_2$, and may additionally be mono-, di- or trisubstituted by $S(O)_mR^2$, $SO_2N(R^2)_2$, SO_3R^2 , or $S(=O)(=NR^2)R^2$.

28. (Previously Presented) A compound of formula I



D denotes phenyl or pyridyl, each of which is unsubstituted or mono- or polysubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR² or CON(R²)₂,

R¹ denotes A, which is mono-, di- or trisubstituted by S(O)_mR², SO₂N(R²)₂, SO₃R², S(=O)(=NR²)R², NR²SO₂R², OSO₂R², OSO₂N(R²)₂ or PO(OR²)₂ and may additionally be mono- or disubstituted by OR³, N(R³)₂, CN, COOR³ or CON(R³)₂,

R² denotes H, A, -[C(R³)₂]_n-Ar', -[C(R³)₂]_n-Het', -[C(R³)₂]_n-cycloalkyl, -[C(R³)₂]_n-N(R³)₂ or -[C(R³)₂]_n-OR³,

R³ denotes H or A,

W denotes -[C(R³)₂]_n-,

X denotes NR³ or O,

Y denotes alkylene, cycloalkylene, Het-diyl or Ar-diyl,

T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms, which is mono-, di- or trisubstituted by =O, and which in addition may be mono-, di- or trisubstituted by R², Hal, A, -[C(R³)₂]_n-Ar, -[C(R³)₂]_n-Het, -[C(R³)₂]_n-cycloalkyl, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²CON(R²)₂, NR²SO₂A, COR², SO₂NR² and/or S(O)_nA, or N(R²)₂ and, if Y = piperidine-1,4-diyl, also R² or cycloalkyl,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by F,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR², N(R²)₂, NO₂, CN, COOR², CON(R²)₂, NR²COA, NR²SO₂A, COR², SO₂N(R²)₂, -[C(R³)₂]_n-COOR², -O-[C(R³)₂]_o-COOR², SO₃H or S(O)_nA,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂, S(O)_nA, -[C(R³)₂]_n-COOR³ or -O-[C(R³)₂]_o-COOR³,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen ($=O$), $=S$, $=N(R^2)_2$, Hal, A, $-[C(R^3)_2]_n-Ar$, $-[C(R^3)_2]_n-Het'$, $-[C(R^3)_2]_n$ -cycloalkyl, $-[C(R^3)_2]_n-OR^2$, $-[C(R^3)_2]_n-N(R^3)_2$, NO_2 , CN , $-[C(R^3)_2]_n-COOR^2$, $-[C(R^3)_2]_n-CON(R^2)_2$, $-[C(R^3)_2]_n-NR^2COA$, $NR^2CON(R^2)_2$, $-[C(R^3)_2]_n-NR^2SO_2A$, COR^2 , $SO_2N(R^2)_2$ and/or $S(O)_nA$,

Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, $=S$, $=N(R^3)_2$, Hal, A, OR^3 , $N(R^3)_2$, NO_2 , CN , $COOR^3$, $CON(R^3)_2$, NR^3COA , $NR^3CON(R^3)_2$, NR^3SO_2A , COR^3 , $SO_2N(R^3)_2$ and/or $S(O)_nA$,

Hal denotes F, Cl, Br or I,

m denotes 1 or 2,

n denotes 0, 1 or 2, and

o denotes 1, 2 or 3,

or a pharmaceutically acceptable salt thereof.

29. (Previously Presented) A compound according to Claim 28, in which

D denotes phenyl which is monosubstituted by Hal,

R^1 denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms which is monosubstituted by $S(O)_mR^2$, $SO_2N(R^2)_2$, SO_3R^2 , $S(=O)(=NR^2)R^2$, $NR^2SO_2R^2$, OSO_2R^2 , $OSO_2N(R^2)_2$ or $PO(OR^2)_2$,

R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

W denotes $-(CH_2)_n-$,

X denotes NH or O,

Y denotes Ar-diyl,

T denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms which is mono- or disubstituted by $=O$, or $N(R^2)_2$

and, if Y = piperidine-1,4-diyl, also R^2 or cycloalkyl,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by $-CH=CH-$ groups and/or also 1-7 H atoms may be replaced by F,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^2 , SO_2A , SO_2NH_2 , $COOR^2$ or CN ,

Hal denotes F, Cl, Br or I,
m denotes 1 or 2, and
n denotes 0, 1 or 2.

30. (New) A compound according to Claim 1, in which
T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms, which is mono-, di- or trisubstituted by =O, and which in addition may be mono-, di- or trisubstituted by R^2 , Hal, A, $-[C(R^3)_2]_n\text{-Ar}$, $-[C(R^3)_2]_n\text{-Het}$, $-[C(R^3)_2]_n\text{-cycloalkyl}$, OR^2 , $N(R^2)_2$, NO_2 , CN, $COOR^2$, $CON(R^2)_2$, NR^2COA , $NR^2CON(R^2)_2$, NR^2SO_2A , COR^2 , SO_2NR^2 and/or $S(O)_nA$.

31. (New) A compound according to Claim 26, in which
T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms, which is mono-, di- or trisubstituted by =O, and which in addition may be mono-, di- or trisubstituted by R^2 , Hal, A, $-[C(R^3)_2]_n\text{-Ar}$, $-[C(R^3)_2]_n\text{-Het}$, $-[C(R^3)_2]_n\text{-cycloalkyl}$, OR^2 , $N(R^2)_2$, NO_2 , CN, $COOR^2$, $CON(R^2)_2$, NR^2COA , $NR^2CON(R^2)_2$, NR^2SO_2A , COR^2 , SO_2NR^2 and/or $S(O)_nA$.

32. (New) A compound according to Claim 28, in which
T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms, which is mono-, di- or trisubstituted by =O, and which in addition may be mono-, di- or trisubstituted by R^2 , Hal, A, $-[C(R^3)_2]_n\text{-Ar}$, $-[C(R^3)_2]_n\text{-Het}$, $-[C(R^3)_2]_n\text{-cycloalkyl}$, OR^2 , $N(R^2)_2$, NO_2 , CN, $COOR^2$, $CON(R^2)_2$, NR^2COA , $NR^2CON(R^2)_2$, NR^2SO_2A , COR^2 , SO_2NR^2 and/or $S(O)_nA$.

33. (New) A compound according to Claim 28, in which
T denotes or $N(R^2)_2$.

34. (New) A compound according to Claim 28, in which
T denotes R^2 or cycloalkyl, and
Y is piperidine-1,4-diyl.